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ABSTRACT
Introduction: Mesh-related complications
especially after vaginal implantation have raised
awareness lately because of severe adverse reac-
tions and legal aspects. About 20% of patients
suffer from complications after mesh insertion
in the anterior vaginal wall. Autologous plasma
coating of meshes prior to implantation has
shown potential to improve the biocompatibil-
ity of meshes in vivo and in vitro. This inno-
vative approach has been developed according
to the IDEAL recommendations for surgical
innovations. The method has still to be assessed
at stage 3 accordingly.
Methods: A protocol is developed for a
prospective single-blinded randomized con-
trolled phase II trial for biocompatibility opti-
mization of anterior vaginal meshes for prolapse
repair by autologous plasma coating versus
non-coated meshes.
Results: The protocol aims at fulfilling the
requirements for stage 3 (assessment) according
to IDEAL. Eligible for inclusion are women with
primary cystocele, requiring a surgical proce-
dure, suitable for randomization, and willing to
be randomized. Participants will be followed up
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by postal questionnaires (6 months post surgery
and 12 months post randomization) and will
also be reviewed in clinic 12 and 24 months
post surgery. Primary endpoint is the assess-
ment of mesh-related complications following
the Clavien–Dindo classifications. QoL, sexual
function assessment, efficacy, and validation of
an already developed long-term register are
considered secondary endpoints. To afford a
calculated 10% reduction of postoperative
complications through plasma-coated meshes
vs. non-coated meshes at 1-year follow-up, a
total 214 women in each arm will be necessary
to achieve 80% power at a significance level of
5%.
Conclusion: The protocol for this randomized
clinical trial represents the conditions to assess
the surgical innovation of plasma coating of
meshes in order to improve the meshes’ bio-
compatibility at stage 3 according to the IDEAL
recommendations.
Keywords: Clinical trial; IDEAL
recommendations; Plasma coating; Prolapse
repair; Quality of life; Surgical innovation;
Surgical mesh; Vaginal prolapse
INTRODUCTION
The Innovation, Development, Exploration,
Assessment, and Long-term study (IDEAL) rec-
ommendations were first introduced in 2009 by
McCulloch et al. to increase the evidence and
transparency requirements for surgical innova-
tions during their entire development and
learning process. The IDEAL recommendations
suggest what types of studies, approaches, and
reporting should be used for surgical innova-
tions and procedures. Table 1 gives an overview
of the different IDEAL stages and the respective
requirements [1–3]. The criteria were extended
in 2016 to IDEAL-D for medical devices to
improve product surveillance, even at preclini-
cal stages of development, in order to rational-
ize regulatory structures and to minimize
regulatory delay [4].
During recent years the development of allo-
plastic materials and respective US Food and
Drug Administration (FDA) warnings
concerning high complication rates associated
with transvaginal placement of surgical meshes
to treat pelvic organ prolapse (POP) and stress
urinary incontinence (SUI) have lead to the
conviction that a detailed and differentiated
evaluation of mesh application is needed. How-
ever, the question of whether traditional or
prosthetic repair of cystocele should be preferred
is still under discussion and not yet backed up
with sufficient and clear data when balancing
best clinical results to lowest complication rates
[5]. Regardless meshes have been increasingly
used in this indication. After two official FDA
warnings in 2008 and 2011 an upgrade in risk
classification for transvaginal meshes was
demanded, allowing the request of premarket
approval and postmarket surveillance studies [6].
Finally, in 2016 the FDA changed the risk class
from II to high risk III for vaginal mesh for POP
treatment [7]. For meshes currently used in
surgeries for hernia, incontinence (SUI), and
prolapse (POP) conditions, respectively, the
optimization of biocompatibility features has
gained increasing focus in clinical and preclinical
research and sophisticated methods have been
developed [8, 9]. However, none of those
approaches have progressed beyond experimen-
tal stages and were therefore not further investi-
gated or applied in humans. In addition, none of
those innovations have been conducted, labeled,
or interpreted according to the IDEAL recom-
mendations. Their potential to be implemented
into clinical use is critical, from both a scientific
and regulatory point of view.
In a very recent publication, Sedrakyan et al.
discussed the potential of the recommendations
for better structuring evaluation and regulation
of medical devices [4]. In particular
implantable devices have been identified as
helpful tools for many patients. Those devices
have also, unfortunately, led to serious adverse
problems in multiple occasions [10–12]. Regu-
latory authorities in both the USA and Europe
are proceeding towards stricter requirements for
new devices to be approved. The FDA now
requires a pivotal clinical trial through its pre-
market approval or within the 510(k) pathway
for vaginal mesh implants. In Europe, the
evolving medical device reform (MDR) will set
comparable standards.
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For reaching the requirements of stage 3 for
medical devices, in particular implantables and/
or substantial modifications, a randomized
controlled trial showing clinical efficacy would
normally be required [13]. However, the IDEAL
recommendations offer alternative experimen-
tal approaches to reach stage 3 level, e.g.,
tracker trials, adaptive designs, and economic
modeling-based studies [4, 14].
Our group has shown in preliminary studies
over 4 years that mesh modification by coating
with autologous plasma results in improved
biocompatibility performances. Those findings
were shown to be consistent under both in vivo
and in vitro conditions [15–18].
In contrast to other researchers covering this
experimental field, from the very beginning our
entire experimental approach has been con-
ducted by following the five-step IDEAL system
for surgical innovations. The project therefore
remains comparable and reproducible at every
single step of development and represents a
unique process of development for a medical
device modification with clinical potential
[19, 20].
As a consequent next step this experimental
approach of mesh coating with autologous
plasma was transferred into human conditions
where the procedure proved to be safe, feasible,
and reproducible [21]. According to the assess-
ment stage requirements a prospective ran-
domized trial comparing the effect of plasma
coating to non-coated meshes would be the
next step in the development process.
Additionally, in order to provide the appro-
priate infrastructure to fulfill stage 4 (long-term
study) our group has already developed a con-
sensus based online registry for registration and
outcome measurement of implant-assisted
operations for POP and female and male SUI.
This registry has already been tested for feasi-
bility [22].
In this current research paper we present a
protocol for a prospective single-blinded ran-
domized controlled trial for biocompatibility
optimization of mesh by autologous plasma
coating. This trial protocol is adapted to the
SPIRIT recommendations for interventional tri-
als [23]. The chosen indication is mesh appli-
cation to the anterior vaginal wall for the
treatment of POP. The primary goal is to
investigate mesh-related complications of plas-
ma-coated meshes compared to naı¨ve, non-
coated meshes. Secondary study goals are QoL
assessment and clinical efficacy for POP
treatment.
METHODS
The presented method of mesh coating with
autologous plasma is based on a German Patent
(DE Patent: 10 2011 000 666.4). The current
study protocol is based on the feasibility
Table 1 IDEAL stages, respective requirements, and already concluded preliminary work according to IDEAL-D within
this project
IDEAL stage Label Primary outcome Study design Reference
0 Preclinical Concept, safety Experimental studies
(animal, cadaver)
[15–18]
1: Idea ‘‘First in human’’ Innovation Case report, case series,
registration
[21]
2:
Development
‘‘Tinkering’’ of device,
few adopters
Development, safety, efﬁcacy Prospective cohort trials [21]
3: Assessment Assessment Compare to standard Randomized controlled
trial or similar
Current
protocol
4: Long term Registry, long-term
evaluation
Quality assurance, identiﬁcation of risk
factors, comparators
Registry [22]
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analysis of an already concluded successful pilot
study with 20 patients [21]. Application of
autologous blood plasma coating is performed
according to the German Pharmaceutical Law
(AMG), the Medical Product Act (MPG), and the
Transfusion Act. In both study centers at least
one investigator will hold the necessary official
regulatory requirements to conduct clinical tri-
als according to both AMG and MPG.
Surgical Procedure
In this study we have chosen the indication of
anterior vaginal wall prolapse, i.e., mainly
cystocele (prolapse of the anterior vaginal wall)
but also combined urethrocele (urethra pro-
lapse) or paravaginal defect (pelvic fascia
defect). Reportedly, in vaginal surgery, the
most common recurrence site is the anterior
vaginal wall with reported failure rates of about
30%. Therefore alloplastic materials have been
and are widely used in this indication to
improve the durability of POP repair and to
reduce the rate of recurrence [24]. The indica-
tion and associated mesh use represent an
appropriate possibility to investigate our
approach of plasma-coated meshes. In this
trial, women will get surgical correction of a
cystocele via anterior vaginal wall repair with
an alloplastic mesh. We will use a commonly
available alloplastic mesh material, which has
been previously tested with plasma coating in
preliminary animal studies (PVDF material).
The particular mesh will be defined before
implementing the trial and will be used in all
participating study centers.
Plasma Coating
Prior to the implantation the modified meshes
will be incubated for at least 30 min with
20–40 ml autologous plasma, which is obtained
from the respective patient by vein puncture
before anesthesia induction. The underlying
surgical technique is not altered by the appli-
cation of our technology and the operation
time will be increased by a maximum of 5 min
as shown in a previous pilot study [21]. Figure 1
gives a simplified illustration of the two main
steps of the procedure.
Protocol Development
A protocol for a prospective single-blinded
randomized controlled phase II trial for bio-
compatibility optimization of anterior vaginal
meshes for prolapse repair by autologous
plasma coating has been developed in collabo-
ration with the participating institutions. The
protocol has been created according to the
CONORT recommendations (http://www.
consort-statement.org). It has been evaluated
and adapted to the SPIRIT (Standard Protocol
Items Recommendations for Interventional
Trials) 2013 Checklist (http://www.spirit-
statement.org/wp-content/uploads/2013/01/
SPIRIT-Checklist-download-8Jan13.pdf). A CON-
SORT diagram is provided for the workflow of this
clinical trial (Fig. 2).
RESULTS
Study Population
In general, this clinical trial will include women
with anterior wall prolapse requiring corrective
surgery (POPQ C III). Potential candidates will
be identified by their treating office-based
gynecologists and urologists and referred to one
of the study centers. Eligible women who
declare an interest in participating in the trial
will receive a patient information leaflet
describing the study and informing about the
scientific background, previous results, etc.
They will also be supplied with a baseline
questionnaire and a consent form as well as an
information sheet concerning the respective
study participation insurance. All patients will
sign an informed consent for randomization
and in order to use their data for the study.
Once those documents are received, every
woman will get a personal study number.
(a) Inclusion criteria: Female
patients[18 years old, affected by C3
stage POP, according to the Pelvic Organ
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Prolapse Quantification system (POP-Q)
classification (score 0–4), indication for
anterior vaginal repair (mesh use),
patients able and willing to complete at
least 24 months of follow-up. Must be
suitable and willing for being
randomized.
(b) Exclusion criteria: Patients with previous
prolapse surgery, hysterectomy, vaginal
surgery or radiotherapy. Comorbidities
representing contraindications for major
surgery. Comorbidities demanding specific
different surgical approach (e.g., fibroids,
scarring/adhesions). Other exclusion
Fig. 1 Mesh coating and application. Plasma retrieval from all patients’ blood probes (a) and mesh insertion with
autologous plasma or native mesh after randomization (b)
Assessement for eligibility 
Possible Exclusion
- Not meeting inclusion criteria
- Declining to participate
Data Analysis
Follow up at 6, 12 and 24 months post 
operatively
Surgery and application of plasma 
coated mesh
Follow up at 6, 12 and 24 months post 
operatively
Surgery and application of naïve, non-
plasma coated mesh
Data Analysis
Randomization 1:1
Fig. 2 CONSORT ﬂow diagram for current trial
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criteria: potential future pregnancies,
infection, chemo- or immunological ther-
apy during the last 3 months, colpocleisis,
obesity, psychiatric illness and pregnancy,
reduced compliance and inability to com-
plete at least 24 months of follow-up.
Study Objectives and Endpoints
Primary Endpoint
• Assessment of mesh-related complications
(erosion, infection, dyspareunia, mesh
shrinkage, chronic pelvic pain[6 weeks)
using the Clavien–Dindo classification [25].
Aim is to answer the question: does plasma
coating of meshes prior to implantation lead
to improved tolerance?
Secondary Endpoints
• Quality of life assessment [use of validated
questionnaires (POP-QoL, ICIQ-SF-2004)].
• Sexual function assessment [use of the vali-
dated German translation of the Pelvic
Organ Prolapse/Incontinence Sexual Ques-
tionnaire IUGA Revised (PISQ-IR)] [26, 27].
• Assessment of functional results with regard
to repair of prolapse, incontinence pelvic
floor sonography and vaginal examination,
efficacy assessed by objective and subjective
cure rates, for POP defined as absence of
vaginal bulge symptoms, SUI defined as
negative stress test and absence of self-re-
ported SUI symptoms (POP-Q questionnaire,
ICIQ-SF 2004 questionnaire) [28, 29].
• Validation of the already created register by
inscription of participating patients [22].
Outcome Measurement
The clinical follow-up will be performed during
the hospital stay at 6, 12, and 24 months
postoperatively.
The complications are followed in accor-
dance with the Clavien–Dindo classification of
surgical complications. Mesh-associated com-
plications are classified according to Cla-
vien–Dindo and ICS/IUGA definition and
include exposure or erosion of mesh, local
infection or fistula, and pelvic pain ([6 weeks)
[29]. Mesh erosion is defined as exposed or
extruded mesh material in the vagina or sur-
rounding pelvic organs. Intraoperative, early
(from discharge and less than 6 weeks), and
delayed complications are differentiated. We
consider the absence of more than grade 2 and/
or any ‘‘delayed’’ Clavien–Dindo complications
to define success.
Before surgery, all patients will provide a
detailed case history and completed a ques-
tionnaire on their urinary and POP symptoms.
The standardized and internationally validated
incontinence questionnaire ICIQ-SF (Interna-
tional Consultation on Incontinence Ques-
tionnaire-Short Form) as a measure for the
psychological strain of incontinence will be
obtained from the patients during the first visit.
The score ranges from zero to 21, with zero
being no strain at all.
The standardized and internationally vali-
dated P-QOL score is used to assess POP symp-
toms. Ratings between 0 and 100 are used to
measure the severity of vaginal prolapse. A
higher score indicates a greater impairment of
quality of life than a lower score. The domain
and symptom questions have individual scores
and are not combined with a whole question-
naire score [30].
Patients undergo a clinical urogynecological
examination, a pelvic ultrasound scan (to
exclude uterine or ovarian disease), and a vagi-
nal inspection in the gynecological and stand-
ing positions at rest and under maximum
straining (cough test) with a full bladder for SUI.
The women are examined in supine position
using the Pelvic Organ Prolapse Quantification
(POP-Q) system of the International Conti-
nence Society (ICS) as a validated and reliable
method to classify a prolapse [31].
Randomization and Blinding
This study cannot be double-blinded since
coating of the mesh is performed in the
operating room prior to implantation of the
mesh. Therefore the study is single-blinded to
the patient. A 1:1 randomization is chosen;
allocation into the two study groups will be
completely randomized using the program
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www.randomizer.at. This randomization appli-
cation will be available as an Internet-based
service. Randomization will be carried out as
close to the time of surgery as is possible.
Statistical Methods and Sample Size
Considerations
In current literature, the complication rate after
mesh-assisted vaginal prolapse repair is assumed
to be about 20% according to published studies
and meta-analyses [28, 32]. In accordance with
experimental and pilot trials we expect a
reduction of mesh-related postoperative com-
plications to 10% at 1-year follow-up by autol-
ogous plasma-coating of mesh prior to
implantation. A total 214 women in each arm
would be required to achieve 80% power at a
significance level of 5%. To test the hypothesis,
a two-sided v2 test is used. On the basis of
experiences in comparable trials, a realistic
estimated percentage of patients lost to fol-
low-up would be 15%. It is planned to actively
stay in contact with the patients (telephoning,
appointments, etc.) in order to reduce this
number. However, allowing for those 15% lost
to follow-up at 1 year would require 252 women
to be recruited to each arm (504 in total).
Both participating centers have a high repu-
tation in the field and regularly perform high
volumes of mesh-applying surgeries in this
indication. The planned and already concluded
advertisement strategies include presentation of
the trial at local scientific meetings, presenta-
tions at loco-regional hospitals, etc. We assume
a steady state recruitment rate of approximately
3 women per month per center, i.e., a total of 72
patients per year. However, considering waver-
ing recruitment numbers possibly related to risk
factors, patient preferences, contraindications
for mesh implantations, etc., we calculated a
realistic recruitment period of 4 years.
Number of Centers Involved
We aim to recruit women from two high-vol-
ume centers with experience of over 70 POP
surgeries per year and extended scientific
research in this field. Those centers are the
Pelvic Floor Centre of the Lukas Hospital
Neuss, Department of Urology, Neuss Ger-
many and the University Hospital for Urology,
Klinikum Oldenburg, School of Medicine and
Health Sciences, Carl von Ossietzky University
Oldenburg. The study will be conducted in
collaboration with the DZITM (German Centre
for Assessment and Evaluation of Innovative
Techniques in Medicine). Both original centers
will have at least one surgeon with at least
10 years of experience in prolapse surgery with
a minimum of 50 procedures per year. Both
centers collaborate with regional gynecological
centers to ensure that at least one additional
surgeon with equal experience level is avail-
able and to increase the recruitment pool. In
case of significant delay in recruitment the
protocol offers the possibility to be amended
in terms of inclusion of additional center(s).
However, center(s) with potential to be added
have to show corresponding quantity and
experience in this surgical indication and need
to satisfy all requirements demanded in this
protocol.
Documentation and Data Handling
Outcome assessment is achieved via participant
self-completed questionnaires, which helps to
avoid an interviewer bias. Documentation of
protocol-required information will be per-
formed via standardized case report forms
which will be reviewed and signed by the
investigator or an appropriate subinvestigator.
All data will be transferred pseudonymously.
Patients and research staff will not be explicitly
informed if the applied mesh was randomly
plasma coated or not during the surgical pro-
cedure. It will not be possible to get this infor-
mation via examination features, etc., either for
the patient or for the physician involved in the
follow-up. In cases of necessary explantation
immunohistochemistry analyses and in vitro
biocompatibility tests of the explanted mesh
will be performed [15].
All participating patients names and respec-
tive confidential information are subject to
medical confidentiality under the German Data
Protection Act. Transmission of data will be
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done in an encrypted format. No access to the
original documents will be given to others not
involved in the trial. Both patient and physician
will sign the informed consent to obtain and
validate it. Patients can quit participation in the
trial at any time without disclosure of their
motives. In this case all relevant data will be
deleted if desired by the patient.
Trial Registration
This trial has been registered at Research Registry
as researchregistry1991 (http://www.researchre
gistry.com/browse-the-registry.html#home/regi
strationdetails/58597cb0ff66105645672327/).
Research Registry is a new online-based
free of cost registry platform launched in 2015
[33]. It is in accordance with the recommen-
dations and allows prospective and retrospec-
tive data registration. This register offers major
advantages like simplicity; it is free for all users
to register and it features open access.
Researchers get immediate visibility of regis-
tered projects.
Ethical Issues
This trial will be performed according to the
Declaration of Helsinki (DoH) for ethical prin-
ciples in human beings [34]. The study proto-
col will get an ethical vote from the Carl von
Ossietzky University, Oldenburg, Germany and
subsequently a vote from the Ethics Commis-
sion of Nordrhein Westphalen representing the
regional official institutions of both study
centers. Although there is no expected
increased risk for patients with plasma-coated
meshes, we will provide a proband insurance
for all participants of the clinical trial. This
article does not contain any new studies with
human or animal subjects performed by any of
the authors.
Funding
Potential institutions will be addressed subse-
quently to publishing the protocol.
DISCUSSION
On the basis of extended in vitro and in vivo
preliminary results we hypothesized that
autologous plasma coating of meshes prior to
implantation improves the mesh’s biocompati-
bility. It should therefore result in a lower
mesh-related complication rate in the inter-
vention group compared to the patient group
with naı¨ve meshes. The entire preliminary
experimental approach has been strictly per-
formed following the IDEAL recommendations
for surgical innovations and our group has
already implemented an online-based registry
as stage 4 (long-term study). In conclusion, this
study has two paramount aims: (1) to investi-
gate the hypothesis of improved biocompati-
bility of plasma-coated meshes compared to
naı¨ve meshes and (2) to fulfill the final and
missing stage 3 (assessment stage) of this novel
method of mesh plasma coating.
When aiming to complete the development
process of a surgical innovation according to
the IDEAL recommendations a clinical trial
(preferably randomized in nature) is necessary
to fulfill the requirements for the assessment
stage. In this particular project we have already
been able to develop an online-based registry
providing with the required tool for the long-
term study. Thus, by publishing a study proto-
col for assessing autologous plasma coating of
meshes in the specific indication of POP surgery
all IDEAL stages will be displayed and com-
pleted for this innovative surgical approach. It
will therefore be the first reported surgical
innovation which has been visualized according
to IDEAL at every step of development [20].
Appropriate trial registration is another
important issue for this study protocol. We have
chosen Research Registry (www.
researchregistry.com). This registry is free of
charge and very easy to handle. In addition, it
features the main reporting recommendations.
The registry had reportedly received 500 regis-
trations by September 2016 [33]. It represents a
valuable tool to officially visualize study proto-
cols even when funding/sponsoring are not
confirmed yet as is the case in this current
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protocol. Chapman and colleagues reported
that one in five surgical randomized controlled
trials (RCT) are discontinued early, and one in
three will not be published 2 years after trial
conclusion [35]. Easy and smart trial registra-
tion tools are important to avoid redundancy
and to help visualizing protocols in order to
prespecify research questions and outcomes
and, last but not least, to document protocols
even when trials cannot be conducted or con-
cluded for unforeseeable reasons (recruitment
problems etc.).
Choice of the appropriate measurement tool
for QoL after POP surgery can be challenging. In
this protocol the assessment of sexual function
will be done with the Pelvic Organ Prolapse/
Incontinence Sexual Questionnaire IUGA
Revised (PISQ-IR) which is the most appropriate
questionnaire and even offers a validated Ger-
man translation [26, 27]. Being composed of 12
different items, three main factor groups are
displayed in this questionnaire: the behavioral
emotive factor (4 items), the physical factor (5
items), and the partner-related factor score (3
items). In a recent study, Vitale and co-workers
successfully used this tool to evaluate sexual
function after cystocele repair with porcine
mesh graft in 20 women and proved it to be a
feasible tool in this indication [36]. For QoL
measurement they use the Short Form-36
(SF-36) validated questionnaire which poses 36
questions and is grouped into eight assessed
categories [37]. It represents a very easy to use
tool for QoL assessment. However, in this pro-
tocol we have chosen the POP-QoL, ICS SF-2004
for QoL assessment which has also been vali-
dated in German and is easy to answer and
commonly used [30].
The paramount strength of this protocol is
the amount of already available supporting data
on the experimental method of plasma coating
for meshes and it’s positive effect on biocom-
patibilty. Several groups have developed coating
strategies of meshes used in prolapse surgery.
Mesh coating with collagen has been mainly
investigated in animal studies showing positive
effects on biocompatibility [38–41]. However,
this approach has not shown convincing results
for the treatment of anterior vaginal wall pro-
lapse when applying it in humans [42, 43].
Other techniques like coating with highly
purified collagen or fetal collagen both in a rat
model [44, 45] and platelet-enriched plasma in
a rabbit model [46] have shown promising bio-
compatibility improvements in vivo. Even a
study using a macaques model for the investi-
gation of extracellular matrix regenerative graft
reported that regenerative extracellular matrix
graft attenuated the negative impact of
polypropylene on the vagina [47]. However,
despite promising, mainly comparative studies
in animals no randomized trial in humans has
been initiated so far to compare any of those
coating strategies to non-coated meshes.
Besides in vitro and in vivo data, the method
has already proven feasible in a pilot study with
20 patients, thereby diminishing safety con-
cerns [21]. In addition, our group has already
developed and successfully implemented a
long-term register for meshes and mesh modi-
fications [22]. Thus, according to IDEAL, the
method needs to be assessed, most preferably in
an RCT setting. Another strength is that this
trial can be easily randomized and sin-
gle-blinded to the patient. Previous data show
that there is no increased risk when applying
meshes which have been previously coated with
autologous plasma.
This study protocol has limitations. An
important limitation is the high number of
required patients (n = 214 not including calcu-
lated lost to follow-up patients) per random-
ization arm which is necessary to prove (or not)
the main outcome goal of decreased mesh-re-
lated complications when using plasma-coated
meshes. As this study is bicentric in nature and
although both centers are high-volume institu-
tions, recruiting 428 or even 504 POP patients
over 4 years is likely to be very difficult. A sta-
tistical advantage can only be shown given this
data. Therefore, trial conclusion could be diffi-
cult recruiting-wise as the number of calculated
patients is high. However, inclusion of addi-
tional centers by amendment is possible
according to the protocol. An important
dilemma of RCT in surgical innovations
becomes visible: practicability may be unrealis-
tic when statistical advantages are the only cri-
teria to assess a surgical innovation. The IDEAL
recommendations are aware of this difficult
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situation and provide alternative designs to
fulfill stage 3 requirements (observational stud-
ies, interrupted time series) [48]. However,
when evaluating the technique of plasma coat-
ing of meshes an RCT is technically feasible as
described.
Another limiting factor for the success of this
trial is the challenge of finding appropriate
funding sources or even financial supporters for
an RCT with a modification of an already
approved medical product. However, after suc-
cessful publication of an approved trial proto-
col, institution funds and public funds will be
targeted.
One can imagine that this trial could show
problems with regard to recruitment or funding.
However, in this particular project it is of out-
most importance that all IDEAL stages are cov-
ered and published accordingly. Thus, it assures
awareness of necessary completion of all IDEAL
stages for the surgical innovation of autologous
plasma coating of meshes in order to evaluate its
potential in broad clinical application.
CONCLUSIONS
The protocol for this randomized clinical trial
represents the conditions to assess the surgical
innovation of plasma coating of meshes in
order to improve the meshes’ biocompatibility
at stage 3 according to the recommendations.
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